Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Retained Earnings (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Retained Earnings for 7 consecutive years, with -$118.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings fell 16.83% to -$118.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$118.5 million, a 16.83% decrease, with the full-year FY2024 number at -$104.2 million, down 11.97% from a year prior.
  • Retained Earnings was -$118.5 million for Q3 2025 at Vivos Therapeutics, down from -$113.1 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$38.7 million in Q1 2021 to a low of -$118.5 million in Q3 2025.
  • A 5-year average of -$82.0 million and a median of -$86.7 million in 2023 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: crashed 58.84% in 2022, then fell 11.62% in 2025.
  • Vivos Therapeutics' Retained Earnings stood at -$55.6 million in 2021, then tumbled by 42.87% to -$79.5 million in 2022, then dropped by 17.09% to -$93.1 million in 2023, then fell by 11.97% to -$104.2 million in 2024, then dropped by 13.7% to -$118.5 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Retained Earnings are -$118.5 million (Q3 2025), -$113.1 million (Q2 2025), and -$108.1 million (Q1 2025).